High growth equities were under some pressure in trading Thursday morning. Overall, the high growth portfolio has fallen about 3%. There is still tariff angst as the president has sent aggressive letters to some trade partners such as Brazil threatening punitive tariffs because of political issues. Further, the QQQs and other indices made all-time highs…
Summary Rubrik’s recent share price pullback offers a compelling entry point, as the company continues to deliver hyper-growth and improving free cash flow margins. Rubrik’s unique preemptive recovery engine and expansion into identity recovery differentiate it in a massive, fast-growing market, supporting sustained 35%+ CAGR. Strategic moves like the Predibase acquisition and Annapurna initiative position…
Summary Oracle’s growth inflection is now a reality, driven by strong demand for OCI, cloud database, and applications, supporting a 20%+ revenue CAGR through 2030. Despite recent share appreciation and near-term free cash flow constraints from heavy capex, I see Oracle’s current share price as an attractive long-term entry point. Oracle’s competitive edge comes from…
We were able to add another 100 shares of Rubrik to the high growth portfolio. Rubrik shares are down this morning and they were down yesterday. They are 15% lower than where they were when they announced their convertible offering. We bought 100 shares at $88.81. This took the position to 1600 shares and the…
We made one opportunistic purchase this morning in the high growth portfolio, acquiring 400 shares of Braze and raising our position to 1100 shares. We bought the shares at $25.51 and this cost $10,210. That has brought our margin balance to $377,510. None of our other orders have been executed. If any go off, I…
I had indicated that I would constrain the margin balance to $350k in the high growth portfolio. I am mindful of the current environment with concerns about wars, tariffs and Fed policies. Economic data is mixed at best with both retail sales and housing starts showing negative trends. I get all that. But there were…
Summary Veeva delivered a standout quarter, raising guidance and demonstrating accelerating growth, with Crossix and Vault CRM driving strong revenue and margin outperformance. Despite macro and competitive risks, I see Veeva’s competitive position strengthening, especially as migrations to Vault CRM and new AI offerings gain traction. VeevaAI, launching in December, is poised to boost growth…
Rubrik announced that it was selling $1 billion of convertible notes today. The likelihood is that the sale gets upsized due to demand. Overall, including the almost inevitable 15% green shoe option, my guess is that the company will raise about $1.2 billion. I expect a coupon rate to be near 0% and a conversion…
Our limit order for Rubrik was executed. We bought 250 shares at $92.99. We now have 1200 shares. The purchase cost $23,255. The new weight of Rubrik in the portfolio is now about 7.6%. To offset the purchase we sold the remaining Nutanix in the portfolio. We sold 250 shares of Nutanix at $76.22. This…
We made some changes in the high growth portfolio this morning. We sold half of our remaining Nutanix position. This doesn’t mean we think that Nutanix doesn’t have a bright future. It almost certainly does, but this is now reflected in its valuation which has gone from attractive to average with the shares up by…